ANGLE plc (GB:AGL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.